Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease.

Bazeley J, Wish JB.

Adv Chronic Kidney Dis. 2019 Jul;26(4):229-236. doi: 10.1053/j.ackd.2019.06.001. Review.

PMID:
31477253
2.

Anemia Treatment After 30 Years of Erythropoietic Stimulating Agents: No Longer Business as Usual?

Wish JB.

Adv Chronic Kidney Dis. 2019 Jul;26(4):225-228. doi: 10.1053/j.ackd.2019.05.006. No abstract available.

PMID:
31477252
3.

Leading the Dialysis Unit: Role of the Medical Director.

Saha S, Wish JB.

Adv Chronic Kidney Dis. 2018 Nov;25(6):499-504. doi: 10.1053/j.ackd.2018.03.004. Review.

PMID:
30527549
4.

Difficult Patient Behavior in Dialysis Facilities.

Janosevic D, Wang AX, Wish JB.

Blood Purif. 2019;47(1-3):254-258. doi: 10.1159/000494592. Epub 2018 Dec 6. Review.

5.

Perspective: Will We Ever Know the Optimal Hgb Level in ESRD?

Wish JB.

J Am Soc Nephrol. 2018 Oct;29(10):2454-2457. doi: 10.1681/ASN.2018040363. Epub 2018 Sep 5. No abstract available.

PMID:
30185470
6.

Biosimilars-Emerging Role in Nephrology.

Wish JB.

Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1391-1398. doi: 10.2215/CJN.01980218. Epub 2018 Aug 6.

PMID:
30082337
7.

Can Emergency Department Visits for Adverse Drug Reactions in Dialysis Patients be Reduced?

Doshi S, Wish JB.

Am J Nephrol. 2018;47(6):435-437. doi: 10.1159/000490064. Epub 2018 Jun 12. No abstract available.

8.

Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.

Gupta N, Wish JB.

Curr Opin Nephrol Hypertens. 2018 Sep;27(5):345-350. doi: 10.1097/MNH.0000000000000430. Review.

PMID:
29746307
9.

Do current quality measures truly reflect the quality of dialysis?

Gupta N, Wish JB.

Semin Dial. 2018 Jul;31(4):406-414. doi: 10.1111/sdi.12685. Epub 2018 Feb 26. Review.

PMID:
29482262
10.

Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?

Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, Macdougall IC, Núñez J, Perahia AJ, Wood JC.

Am J Nephrol. 2018;47(2):72-83. doi: 10.1159/000486968. Epub 2018 Feb 13.

11.

Employment among Patients on Dialysis: An Unfulfilled Promise.

Hallab A, Wish JB.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):203-204. doi: 10.2215/CJN.13491217. Epub 2018 Jan 18. No abstract available.

12.

Moving Beyond the Assumed: Improving Fistula Success Rates.

Wish JB, Moe SM.

J Am Soc Nephrol. 2017 Oct;28(10):2827-2829. doi: 10.1681/ASN.2017060663. Epub 2017 Jul 21. No abstract available.

13.

Emerging treatments for anemia in patients with CKD and ESRD.

Wish JB.

Nephrol News Issues. 2017 Apr;31(4):18-22, 24, 26, 29. No abstract available.

PMID:
30707801
14.

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.

Gupta N, Wish JB.

Am J Kidney Dis. 2017 Jun;69(6):815-826. doi: 10.1053/j.ajkd.2016.12.011. Epub 2017 Feb 24. Review. Erratum in: Am J Kidney Dis. 2017 Jun;69(6):869.

15.

What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Benefits of Intravenous Iron.

Wish JB.

Semin Dial. 2017 Jan;30(1):20-22. doi: 10.1111/sdi.12552. Epub 2016 Sep 27. No abstract available.

PMID:
27679413
16.

Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Wish JB, Charytan C, Chertow GM, Kalantar-Zadeh K, Kliger AS, Rubin RJ, Yee J, Fishbane S.

Am J Kidney Dis. 2016 Dec;68(6):843-852. doi: 10.1053/j.ajkd.2016.06.022. Epub 2016 Sep 3.

PMID:
27599628
17.

Nephrologists Versus Peripherally Inserted Central Catheters: Are the PICCs Winning?

Kalloo S, Wish JB.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1333-4. doi: 10.2215/CJN.05750516. Epub 2016 Jun 23. No abstract available.

18.

Management of the Hemodialysis Unit: Core Curriculum 2016.

Blankschaen SM, Saha S, Wish JB.

Am J Kidney Dis. 2016 Aug;68(2):316-327. doi: 10.1053/j.ajkd.2016.03.417. Epub 2016 Apr 29. No abstract available.

19.

New Options for Iron Supplementation in Maintenance Hemodialysis Patients.

Vaziri ND, Kalantar-Zadeh K, Wish JB.

Am J Kidney Dis. 2016 Mar;67(3):367-75. doi: 10.1053/j.ajkd.2015.09.031. Epub 2015 Nov 24. Review.

20.

Hemodialysis Access in Patients With Failed Kidney Transplants: Nephrologist, Heal Thyself.

Khalil AK, Wish JB.

Am J Kidney Dis. 2015 Oct;66(4):555-7. doi: 10.1053/j.ajkd.2015.07.003. No abstract available.

PMID:
26408234
21.

Quality Measurement in Wonderland: The Curious Case of a Dialysis Readmissions Measure.

Fishbane S, Wish JB.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):190-4. doi: 10.2215/CJN.02770315. Epub 2015 Jul 16. Review.

22.

Medical Director Responsibilities to the ESRD Network.

DeOreo PB, Wish JB.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1852-8. doi: 10.2215/CJN.05350514. Epub 2014 Sep 25.

23.

Catheter last, fistula not-so-first.

Wish JB.

J Am Soc Nephrol. 2015 Jan;26(1):5-7. doi: 10.1681/ASN.2014060594. Epub 2014 Jul 25. No abstract available.

24.

The approval process for biosimilar erythropoiesis-stimulating agents.

Wish JB.

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1645-51. doi: 10.2215/CJN.01770214. Epub 2014 Jun 26.

25.

The iron story: red smoke and magnetism?

Wish JB.

Nephrol News Issues. 2014 Feb;28(2):2-3. No abstract available.

PMID:
24649743
26.

The role of 30-day readmission as a measure of quality.

Wish JB.

Clin J Am Soc Nephrol. 2014 Mar;9(3):440-2. doi: 10.2215/CJN.00240114. Epub 2014 Feb 7. No abstract available.

27.

Management of anemia in patients with kidney disease in 2013 and beyond.

Wish JB.

Nephrol News Issues. 2013 Jun;27(7):Supp 1-3. No abstract available.

PMID:
23855140
28.

The KDIGO anemia guideline: can reason triumph over regulation?

Wish JB.

Nephrol News Issues. 2012 Dec;26(13):20, 22-3. No abstract available.

PMID:
23346853
29.

Systemic barriers to optimal hemodialysis access.

Donca IZ, Wish JB.

Semin Nephrol. 2012 Nov;32(6):519-29. doi: 10.1016/j.semnephrol.2012.10.002.

PMID:
23217331
30.

ESRD Networks: past, present, and challenges for the future.

Wish JB, Meyer KB.

Clin J Am Soc Nephrol. 2012 Nov;7(11):1907-14. doi: 10.2215/CJN.01450212. Epub 2012 Sep 13.

31.

Are consistency and individualization mutually exclusive in erythropoiesis-stimulating agent therapy?

Wish JB.

Am J Kidney Dis. 2012 Sep;60(3):340-2. doi: 10.1053/j.ajkd.2012.06.007. No abstract available.

PMID:
22901630
32.

A physician's perseverance uncovers problems in a key nephrology study.

Fishbane S, Wish JB.

Kidney Int. 2012 Jul;82(2):135-7. doi: 10.1038/ki.2012.122.

33.

Can better understanding and use of treatment center performance feedback improve hemodialysis care? A role for the medical director.

DeOreo PB, Wilson R, Wish JB.

Semin Dial. 2012 May;25(3):290-3. doi: 10.1111/j.1525-139X.2012.01075.x. Epub 2012 Apr 12. Review. No abstract available.

PMID:
22494265
34.

Prevalence of arteriovenous fistulas in incident hemodialysis patients: correlation with patient factors that may be associated with maturation failure.

Lilly MP, Lynch JR, Wish JB, Huff ED, Chen SC, Armistead NC, McClellan WM.

Am J Kidney Dis. 2012 Apr;59(4):541-9. doi: 10.1053/j.ajkd.2011.11.038. Epub 2012 Feb 17.

PMID:
22342212
35.

Erythropoiesis-stimulating agents and pure red-cell aplasia: you can't fool Mother Nature.

Wish JB.

Kidney Int. 2011 Jul;80(1):11-3. doi: 10.1038/ki.2011.45.

36.

Hemoglobin variability as a predictor of mortality: What's a practitioner to do?

Wish JB.

Am J Kidney Dis. 2011 Feb;57(2):190-3. doi: 10.1053/j.ajkd.2010.11.004. No abstract available.

PMID:
21251539
37.
38.

What is expected of a medical director in the Centers for Medicare and Medicaid Services Conditions of Coverage?

Wish JB.

Blood Purif. 2011;31(1-3):61-5. doi: 10.1159/000321836. Epub 2011 Jan 10.

39.

Vascular access for dialysis in the United States: progress, hurdles, controversies, and the future.

Wish JB.

Semin Dial. 2010 Nov-Dec;23(6):614-8. doi: 10.1111/j.1525-139X.2010.00797.x. Epub 2010 Dec 20. Review.

PMID:
21175835
40.

Fistula First: myth vs. fact.

Wish JB.

Nephrol News Issues. 2010 Apr;24(4):36, 39-41.

PMID:
20458993
41.

Anemia in renal disease: diagnosis and management.

Lankhorst CE, Wish JB.

Blood Rev. 2010 Jan;24(1):39-47. doi: 10.1016/j.blre.2009.09.001. Epub 2009 Oct 14. Review.

PMID:
19833421
42.

Dialysis delivery in Canada and the United States: a view from the trenches.

Mendelssohn DC, Wish JB.

Am J Kidney Dis. 2009 Nov;54(5):954-64. doi: 10.1053/j.ajkd.2009.05.023. Epub 2009 Sep 2.

PMID:
19726118
43.

Posttransplant anemia: the role of sirolimus.

Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB.

Kidney Int. 2009 Aug;76(4):376-82. doi: 10.1038/ki.2009.231. Epub 2009 Jun 24. Review.

44.

Past, present, and future of chronic kidney disease anemia management in the United States.

Wish JB.

Adv Chronic Kidney Dis. 2009 Mar;16(2):101-8. doi: 10.1053/j.ackd.2008.12.005. Review.

PMID:
19233069
45.

New ESRD clinical performance measures and data collection system: progress and pitfalls.

Wish JB.

Nephrol News Issues. 2008 Jul;22(8):12-3. No abstract available.

PMID:
18711877
46.

Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease.

Wish JB, Nassar GM, Schulman K, del Aguila M, Provenzano R.

Clin Nephrol. 2008 Apr;69(4):251-9.

PMID:
18397699
47.

Intravenous iron: not just for hemodialysis patients anymore.

Wish JB.

Perit Dial Int. 2008 Mar-Apr;28(2):126-9. No abstract available.

PMID:
18332445
49.

Assessing iron status: beyond serum ferritin and transferrin saturation.

Wish JB.

Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S4-8. Review.

50.

Should patients get EPO subcutaneously?

Wish JB.

Nephrol News Issues. 2006 Aug;20(9):12. No abstract available.

PMID:
16916054

Supplemental Content

Support Center